Strata Skin Sciences (formerly MELA Sciences, Inc.) is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| SSKN | STRATA Skin Sciences, Inc. | 2025-10-16 21:18:37 | 1.92 | -0.16 | -7.69 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SSKN | 0001051514 | STRATA Skin Sciences, Inc. | US86272A3059 | 529900JXBTG5OB59PM04 | 133986004 | Nasdaq | 3841 | Surgical & Medical Instruments & Apparatus | 1231 | DE | 5 WALNUT GROVE DRIVE | HORSHAM | PA | 19044 | UNITED STATES | US | 215-619-3200 | 5 WALNUT GROVE DRIVE, HORSHAM, PA, 19044 | 5 WALNUT GROVE DRIVE, HORSHAM, PA, 19044 | MELA SCIENCES, INC. /NY | — | 1989-01-01 | — | — | https://www.strataskinsciences.com | 4,958,532 | 4,171,161 | 4,171,161 | Strata Skin Sciences (formerly MELA Sciences, Inc.) is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations. | 2025-10-10 23:59:00 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 4,958,532 | -12,306,224 | -71.2795 | 4,171,161 | -30,889,793 | -88.1031 |
| 2023 | 17,264,756 | -137,425 | -0.7897 | 35,060,954 | 179,501 | 0.5146 |
| 2022 | 17,402,181 | -8,521,170 | -32.8706 | 34,881,453 | 158,407 | 0.4562 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Shmuel Gov | Chief Operating Officer | 2023 | 303,819 | — | — | 135,240 | 25,200 | 683,789 |
| Dolev Rafaeli | Chief Executive Officer, President, Chairman Of The Board | 2023 | 67,308 | — | — | 0 | 4,858 | 662,167 |
| Robert Moccia | Chief Executive Officer, Director, President | 2023 | 461,113 | — | — | 284,537 | 201,338 | 1,049,213 |
| Chris Lesovitz | Chief Financial Officer | 2023 | 282,308 | — | — | 187,500 | 23,378 | 701,886 |
| Robert Moccia | Chief Executive Officer, Director, President | 2022 | 510,731 | — | — | 299,677 | 27,200 | 982,528 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 106 |
| 2023 | 99 |
| 2022 | 114 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 33,562,000 | 33,358,000 | 36,161,000 |
| Cost Of Revenue | 14,481,000 | 14,897,000 | 14,393,000 |
| Gross Profit | 19,081,000 | 18,461,000 | 21,768,000 |
| Research And Development Expenses | 883,000 | 1,317,000 | 1,029,000 |
| General And Administrative Expenses | 11,303,000 | 10,508,000 | 10,087,000 |
| Operating Expenses | 28,336,000 | 27,065,000 | 26,417,000 |
| Operating Income | -9,255,000 | -8,604,000 | -4,649,000 |
| Net Income | -10,086,000 | -10,830,000 | -5,549,000 |
| Earnings Per Share Basic | -2.65 | -0.31 | -0.16 |
| Earnings Per Share Diluted | -2.65 | -0.31 | -0.16 |
| Weighted Average Shares Outstanding Basic | 3,807,186 | 34,920,291 | 34,712,246 |
| Weighted Average Shares Outstanding Diluted | 3,807,186 | 34,920,291 | 34,712,246 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 7,261,000 | 6,784,000 | 5,434,000 |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | 5,253,000 | 4,440,000 | 4,471,000 |
| Inventories | 2,246,000 | 2,673,000 | 5,547,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 16,595,000 | 15,543,000 | 17,504,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 10,061,000 | 11,778,000 | 7,498,000 |
| Other Assets Non Current | 231,000 | 231,000 | 98,000 |
| Total Assets Non Current | 1,300,000 | 800,000 | 600,000 |
| Total Assets | 36,157,000 | 42,016,000 | 52,272,000 |
| Accounts Payable | 2,433,000 | 3,343,000 | 3,425,000 |
| Deferred Revenue | 2,241,000 | 2,120,000 | 2,778,000 |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 8,593,000 | 6,306,000 | 6,555,000 |
| Total Liabilities Current | 14,625,000 | 12,174,000 | 13,426,000 |
| Long Term Debt | 15,000,000 | 15,000,000 | 8,000,000 |
| Other Liabilities Non Current | — | — | — |
| Total Liabilities Non Current | 16,560,000 | 17,154,000 | 17,015,000 |
| Total Liabilities | 31,185,000 | 29,328,000 | 30,441,000 |
| Common Stock | 4,000 | 35,000 | 35,000 |
| Retained Earnings | -248,144,000 | -238,058,000 | -227,228,000 |
| Accumulated Other Comprehensive Income | — | — | — |
| Total Shareholders Equity | 4,972,000 | 12,688,000 | 21,831,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 4,968,000 | 5,553,000 | 5,293,000 |
| Share Based Compensation Expense | 427,000 | 1,303,000 | 1,466,000 |
| Other Non Cash Income Expense | -49,000 | -72,000 | -52,000 |
| Change In Accounts Receivable | 631,000 | -141,000 | 1,145,000 |
| Change In Inventories | -572,000 | -689,000 | 1,524,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | -954,000 | -100,000 | 603,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | 188,000 | -519,000 | -1,108,000 |
| Purchases Of Marketable Securities | — | — | — |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | 1,636,000 | 5,019,000 | 3,552,000 |
| Acquisition Of Business | — | 0 | 631,000 |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -1,636,000 | -5,019,000 | -4,183,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 1,943,000 | — | — |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | 0 | 7,000,000 | 0 |
| Repayment Of Long Term Debt | — | — | 0 |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 1,925,000 | 6,861,000 | -500,000 |
| Change In Cash | 477,000 | 1,323,000 | -5,791,000 |
| Cash At End Of Period | 7,261,000 | 6,784,000 | 5,434,000 |
| Income Taxes Paid | 23,000 | 22,000 | 19,000 |
| Interest Paid | 1,973,000 | 1,415,000 | 744,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | -2.65 | -0.31 | -0.16 |
| Price To Earnings Ratio | -1.0981 | -17.7452 | -49.3813 |
| Earnings Growth Rate | 754.8387 | 93.75 | 100 |
| Price Earnings To Growth Ratio | -0.0015 | -0.1893 | -0.4938 |
| Book Value Per Share | 1.306 | 0.3633 | 0.6289 |
| Price To Book Ratio | 2.2283 | 15.14 | 12.5629 |
| Ebitda | -2,988,000 | -3,615,000 | 689,000 |
| Enterprise Value | 18,817,911.26 | 200,312,520.791 | 276,827,455.646 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 3.0169 | 1.1822 | 0.3665 |
| Capital Expenditures | 3,251,000 | 9,833,000 | 5,908,000 |
| Free Cash Flow | -3,063,000 | -10,352,000 | -7,016,000 |
| Return On Equity | -2.0286 | -0.8536 | -0.2542 |
| One Year Beta | 0.0107 | -0.0673 | 0.2963 |
| Three Year Beta | 0.1849 | 0.3169 | 0.6135 |
| Five Year Beta | 0.5197 | 0.579 | 0.6332 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Rafaeli Dolev | Director, Chief Executive Officer | 2025-05-13 | 58,000 | A | 232,557 |
| Gillings John T | Chief Accounting Officer | 2025-05-13 | 30,000 | A | 30,000 |
| Gov Shmuel | Chief Operating Officer | 2025-05-13 | 40,000 | A | 137,125 |
| Allgeier Christina L | Director | 2024-10-29 | 20,000 | A | 20,000 |
| Rafaeli Dolev | Director, Chief Executive Officer | 2024-07-15 | 19,100 | A | 143,156 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| MORGAN STANLEY | 2025-06-30 | 2 | 1 | 2 |
| Tower Research Capital LLC (TRC) | 2025-06-30 | 33,757 | 14,741 | 2.29 |
| Nantahala Capital Management, LLC | 2025-06-30 | 924,970 | 403,917 | 2.29 |
| BANK OF AMERICA CORP /DE/ | 2025-06-30 | 451 | 197 | 2.2893 |
| UBS Group AG | 2025-06-30 | 16,740 | 7,310 | 2.29 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| VANGUARD INDEX FUNDS | 2025-06-30 | Institutional Select Shares | VSEMX | 23,545 | 54,153.5 | 0.0 |
| VANGUARD INDEX FUNDS | 2025-06-30 | Institutional Plus Shares | VEMPX | 23,545 | 54,153.5 | 0.0 |
| VANGUARD INDEX FUNDS | 2025-06-30 | ETF Shares | VXF | 23,545 | 54,153.5 | 0.0 |
| VANGUARD INDEX FUNDS | 2025-06-30 | Institutional Shares | VIEIX | 23,545 | 54,153.5 | 0.0 |
| VANGUARD INDEX FUNDS | 2025-06-30 | Admiral Shares | VEXAX | 23,545 | 54,153.5 | 0.0 |